Search Results
Your search for all items matches 35147 pages
Showing 7001 - 7050From Iran to Silicon Valley, a Cancer Survivor Shares Her Story
The Iranian revolution of 1979 transformed Iran from an absolute monarchy under Shah Mohammad Pahlavi to an Islamist republic under Ayatollah Khomeini. The author of a new book called The Magic of Normal, Maky Zanganeh, PhD, was born in Iran in 1970. As a young woman, she experienced the war in her ...
Immunotherapy in B-Cell Non-Hodgkin Lymphomas: Off-the-Shelf Bispecific Antibodies
Chimeric antigen receptor (CAR) T-cell therapies are a significant advance, but they require careful patient selection, dependency on patients’ own T cells, lymphodepleting chemotherapy, possible bridging therapy, manufacturing timelines with extensive health-care coordination and cost, in...
Incidental Findings on Low-Dose CT Lung Cancer Screening in the NLST and Risk of Respiratory Disease Mortality
In an analysis of data from the National Lung Screening Trial (NLST) reported in Chest, Paul F. Pinsky, PhD, of the Division of Cancer Prevention, National Cancer Institute, and colleagues found that incidental respiratory disease–related findings on low-dose computed tomography (CT) screening...
Expert Point of View: Amandeep Salhotra, MD
Amandeep Salhotra, MD, Associate Professor of Leukemia at City of Hope, in California, said this study should form the basis for a prospective phase III study in which older patients with AML (60–75 years) should have equal chance at randomization to either arm to remove bias on the part of...
AML Study Shows Benefit of CPX-351 vs Hypomethylating Agent Plus Venetoclax in Subgroup of Older Adults
For older patients with acute myeloid leukemia (AML), front-line treatment with liposomal daunorubicin/cytarabine (CPX-351) appears to be equivalent to treatment with a hypomethylating agent plus venetoclax, according to data presented at the 2021 American Society of Hematology (ASH) Annual Meeting ...
Expert Point of View: Mikkael Sekeres, MD
Mikkael Sekeres, MD, Chief of the Division of Hematology at the University of Miami Health System and a hematologist at Sylvester Comprehensive Cancer Center, applauded the IDIOME1 and IDEAL2 investigators for conducting studies. These studies, he noted, were “very difficult because of the rarity...
IDH1/2 Inhibitors Show Activity in Patients With Myelodysplastic Syndrome
The oral targeted small-molecule inhibitors of mutant IDH1 and IDH2 appear to be active in patients with myelodysplastic syndrome (MDS) harboring these mutations, according to two phase II trials by the Groupe Francophone des Myélodysplasies (GFM) and its German colleagues in the European MDS...
Association of Lifestyle and Cardiovascular Risk Factors With Hospitalization for Heart Failure Subtypes in Breast Cancer Survivors
In an analysis from the Women’s Health Initiative reported in JACC: CardioOncology, Kerryn W. Reding, PhD, MPH, RN, of the University of Washington at Seattle, and colleagues, identified the incidence of hospitalization for heart failure among postmenopausal breast cancer survivors. They reported...
Immune Checkpoint Inhibitors in Neoadjuvant or Adjuvant Therapy for Triple-Negative Breast Cancer: The Paradigm Shifts
The “holy grail” of triple-negative breast cancer therapy has been effective incorporation of drugs to improve outcomes in the early nonmetastatic setting. Although outcomes have improved with better chemotherapy drugs and schedules, triple-negative breast cancer still carries the worst prognosis...
Addition of Pembrolizumab to Chemotherapy Improves Event-Free Survival in Triple-Negative Breast Cancer
As reported in The New England Journal of Medicine by Peter Schmid, MD, PhD, of Barts Cancer Institute, Queen Mary University of London, and colleagues, a preplanned interim analysis of the phase III KEYNOTE-522 trial has shown improved event-free survival with the addition of pembrolizumab to...
MEK Inhibition Is Now a Standard of Care in Recurrent Low-Grade Serous Ovarian Cancer: What Next?
As summarized in this issue of The ASCO Post, the highly anticipated results of the GOG 281/LOGS study, which randomly assigned patients with recurrent low-grade serous ovarian cancer to the MEK inhibitor trametinib vs standard-of-care chemotherapy or endocrine therapy, have now been reported by...
Trametinib Improves Progression-Free Survival vs Standard-of-Care Treatment in Recurrent Low-Grade Serous Ovarian Carcinoma
As reported in The Lancet by David M. Gershenson, MD, of the Department of Gynecologic Oncology and Reproductive Medicine, MD Anderson Cancer Center, Houston, and colleagues, the phase II/III GOG 281/LOGS trial showed that trametinib improved progression-free survival vs standard-of-care treatment...
Fixed-Dose Nivolumab and Relatlimab-rmbw for Unresectable or Metastatic Melanoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On March 18, 2022, fixed-dose nivolumab and...
New Report Offers Guidance for Standardizing Data on Sex, Gender, Sexual Orientation
On March 9, 2022, the National Academies of Sciences, Engineering, and Medicine (NASEM) issued a new report, Measuring Sex, Gender Identity, and Sexual Orientation, recommending the National Institutes of Health (NIH) implement new guidelines to standardize the collection of data on sex, gender,...
War in Ukraine: Statistics Do Not Keep Pace With Reality
Editor’s Note: The following is adapted from Dr. Hrynkiv’s presentation at the March 18 ASCO/ECO Briefing: Cancer Care During the War in Ukraine. Find resources for impacted patients and providers at asco.org/ukraine and onco-help.org. Official statistics regarding damage and losses in Ukraine are...
Philip D. Greenberg, MD, FAACR, Voted AACR President-Elect for 2022–2023
The members of the American Association for Cancer Research (AACR) have chosen Philip D. Greenberg, MD, FAACR, as the Association’s President-Elect for 2022–2023. Dr. Greenberg is the Rona Jaffe Foundation Endowed Chair and Professor and Head of the Program in Immunology, Clinical Research...
Clinical Trials Updates in the Treatment of Older Adults With Gastrointestinal Malignancies
The theme of the 2022 ASCO Gastrointestinal Cancers Symposium was “Accelerating Access to Precision Care Through Innovation.” Several studies presented at this meeting focused on older patients, who represent the majority of patients with gastrointestinal malignancies. Data reviewed at the meeting...
Norman Sharpless, MD, to Step Down as Director of the NCI
Norman E. Sharpless, MD, has announced that he has decided to step down from his position as Director of the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), a position he has held since 2017. Dr. Sharpless will continue as NCI Director through April 29, 2022, to...
Expert Point of View: Angela DeMichele, MD, MSCE
Abstract discussant, Angela DeMichele, MD, MSCE, the Alan and Jill Miller Professor in Breast Cancer Excellence at the Perelman School of Medicine of the University of Pennsylvania, Philadelphia, complimented the study design and conduct of the ABC trial while exploring several possible...
Phase III Trial Evaluates the Role of Aspirin in Preventing Breast Cancer Recurrence
Taking aspirin daily does not prevent breast cancer recurrence, according to research presented during the February ASCO Plenary Series Program.1 Results of the double-blind phase III study of more than 3,000 patients with high-risk, HER2-negative breast cancer showed no improvement in invasive...
Expert Point of View: Martin Reck, MD, PhD
The discussant of the PEARLS/KEYNOTE-091 trial, Martin Reck, MD, PhD, underscored the need to do more in the perioperative management of patients with early-stage non–small cell lung cancer (NSCLC) to improve rates of overall survival and relapse after surgery. Dr. Reck is Head of the Department of ...
Study Reports Adjuvant Pembrolizumab Improves Disease-Free Survival in Early-Stage NSCLC
Adjuvant pembrolizumab improves disease-free survival compared with placebo in patients with early-stage non–small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy when indicated. These findings from the PEARLS/KEYNOTE-091 trial were reported in a European Society for ...
Why Are Many Women Overdue for Cervical Cancer Screening?
Cervical cancer screening has reduced new cases and deaths from the disease over the past 50 years. However, the percentage of women in the United States who are overdue for cervical cancer screening has been growing, and the reasons have not been clear. To better understand the decline in cervical ...
Expert Point of View: Amit M. Oza, MD, MBBS
The invited discussant of the phase III ENGOT-EN5/GOG-3055/SIENDO trial was Amit M. Oza, MD, MBBS, Head of the Division of Medical Oncology & Hematology at University Health Network/Mount Sinai, Director of Clinical Research and Clinical Cancer Research Unit at Princess Margaret Hospital, and ...
Selinexor Improves Progression-Free Survival in Endometrial Cancer
In the treatment of advanced endometrial cancer, maintenance therapy with oral selinexor after response to first-line chemotherapy may result in a significantly reduced risk of disease progression, according to the results of the global phase III ENGOT-EN5/GOG-3055/SIENDO trial, presented at the...
Andrew Chapman, DO, FACP, Appointed Director of the Sidney Kimmel Cancer Center–Jefferson Health, Philadelphia
Andrew Chapman, DO, FACP, has been named Director of the Sidney Kimmel Cancer Center–Jefferson Health, with locations in Philadelphia and nearby areas in Pennsylvania and New Jersey. He has also been named the Center’s Executive Vice President for Oncology Services. He has served as the Center’s...
Fox Chase Cancer Center Appoints Elizabeth Plimack, MD, MS, as Deputy Director
Elizabeth Plimack, MD, MS, has been appointed to Deputy Director at Fox Chase Cancer Center in Philadelphia, according to Jonathan Chernoff, MD, PhD, Cancer Center Director at Fox Chase. Dr. Plimack is Chief of the Division of Genitourinary Medical Oncology and Professor in the Department of...
Selinexor in Previously Treated Advanced Dedifferentiated Liposarcoma
In the phase II/III SEAL trial reported in the the Journal of Clinical Oncology, Gounder et al found that selinexor significantly improved progression-free survival and time to subsequent treatment in previously treated advanced dedifferentiated liposarcoma, with the greatest benefit observed in...
Less Prostate Cancer Screening Reduces Overdiagnosis but May Miss Aggressive Cases
Over the past 15 years, public health authorities have downgraded recommendations for the prostate-specific antigen (PSA) test as a screening tool to reduce the overdiagnosis and overtreatment of men with low-grade prostate cancer. Researchers from Weill Cornell Medicine have found that while these ...
Expert Point of View: Charu Aggarwal, MD, MPH
Charu Aggarwal, MD, MPH, discussant of the CHOICE-01 trial, underscored the “tremendous progress” that’s been made over the past 2 decades in the management of metastatic non–small cell lung cancer, with overall survival increasing from less than 1 year with the use of combination chemotherapy to...
New Factors That Can Predict Breast Cancer Recurrence Identified
Genetics and other factors that can determine if a woman is at risk for a recurrence of breast cancer have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Center, providing new research avenues for preventing a new tumor from developing. The discovery was made possible...
CHOICE-01: Toripalimab Plus Chemotherapy Improves Survival in Advanced NSCLC Without Actionable Mutations
Adding the PD-1 inhibitor toripalimab to chemotherapy significantly improved survival compared with chemotherapy alone in patients with advanced non–small cell lung cancer (NSCLC) without EGFR/ALK mutations, according to research presented during the 2022 ASCO Monthly Plenary Series.1 At the...
Expert Point of View: Julie A. Margenthaler, MD, FACS
Julie A. Margenthaler, MD, FACS, Professor of Surgery at Washington University School of Medicine, St. Louis, told The ASCO Post that routine clinical examination may not be enough to properly identify lymph node involvement in patients with triple-negative breast cancer. “Given that we now have...
Is Neoadjuvant Pembrolizumab Underused in the Treatment of Early-Stage Triple-Negative Breast Cancer?
Neoadjuvant pembrolizumab has been approved in combination with chemotherapy for high-risk, early-stage, triple-negative breast cancer, but not all patients with node-positive disease have been able to receive the regimen, according to data presented during the Society of Surgical Oncology 2022...
Overall Survival in KEYNOTE-177: Pembrolizumab vs Chemotherapy in Microsatellite Instability–High or Mismatch Repair–Deficient Metastatic Colorectal Cancer
As reported in The Lancet Oncology by Diaz et al, the final overall survival analysis of the phase III KEYNOTE-177 trial did not show a significant improvement with pembrolizumab vs chemotherapy in patients with newly diagnosed microsatellite instability–high or mismatch repair–deficient metastatic ...
Phase III Trials and Tribulations
Imagine this. You are a large pharmaceutical company that launches an international randomized phase III trial to assess whether one of your drugs improves the outcome of patients with a common type of cancer. The trial was solidly backed by preclinical evidence that the drug target was essential ...
CheckMate 816: Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC
As reported in The New England Journal of Medicine by Forde et al, the phase III CheckMate 816 trial has shown improved pathologic complete response rate and event-free survival with the addition of nivolumab to platinum-based chemotherapy in the neoadjuvant treatment of resectable non–small cell...
Internal Mammary Node Irradiation in Node-Positive Early Breast Cancer: 15-Year Outcomes
As reported in the Journal of Clinical Oncology by Thorsen et al, 15-year follow-up of the Danish Breast Cancer Group Internal Mammary Node study indicates continued survival benefit with internal mammary node irradiation in women with right breast tumors vs without such therapy in those with left...
Expert Point of View: Adil Daud, MBBS, and Georgina V. Long, MBBS, PhD
The invited discussant of the RELATIVITY-047 trial, Adil Daud, MBBS, said the findings1 “mark a major advance for immunotherapy beyond CTLA-4 and PD-1” as upfront treatment for advanced melanoma. However, the findings trigger a host of questions for clinicians. Dr. Daud is Co-Director of the...
RELATIVITY-047 Update: Novel Immunotherapy Duo Delays Disease Progression in Advanced Melanoma
A novel immunotherapeutic combination that targets PD-1 and the LAG-3 pathway significantly delayed disease progression as a first-line treatment of advanced or unresectable melanoma. Updated results of the global phase III RELATIVITY-047 trial validated the study’s initial findings and were...
Study Shows Medical Financial Hardship Increases Mortality Risk for Cancer Survivors
New findings from a large national study led by researchers at the American Cancer Society (ACS) show cancer survivors in the United States who reported medical financial hardship had a higher mortality risk than cancer survivors without financial hardship. Medical financial hardship was measured...
Virtual Panel Explores Impact of Racism on the Cancer Burden Facing Asian Americans
On July 21, 2021, the Oncology Center of Excellence at the U.S. Food and Drug Administration (FDA) convened a panel discussion entitled “Conversations on Cancer” to address the significant cancer disparities facing Asian Americans. The virtual “conversation” focused on the unfair burden impacting...
Nominations Open for King Hussein Award for Cancer Research
The Board of Directors for the King Hussein Award for Cancer Research is currently accepting applications for its 2022 honorees. Established in 2020 in memory of His Majesty the late King Hussein bin Talal of Jordan, the award promotes and celebrates cancer research efforts across the Arab world,...
Role of 21-Gene Recurrence Score and Preoperative Endocrine Therapy Response in Guiding Treatment in Early Hormone Receptor–Positive, HER2-Negative Breast Cancer
In a German trial (WSG-ADAPT-HR1/HER2–) reported in the Journal of Clinical Oncology, Nitz et al found no difference in invasive disease-free survival between women with early hormone receptor–positive, HER2-negative breast cancer with zero to three positive nodes who had a 21-gene recurrence score ...
Addition of Nintedanib to Neoadjuvant Gemcitabine/Cisplatin in Locally Advanced Muscle-Invasive Bladder Cancer
In the UK phase II NEOBLADE trial reported in The Lancet Oncology, Hussain et al found that the addition of nintedanib to neoadjuvant gemcitabine/cisplatin did not improve pathologic complete response rate in patients with locally advanced muscle-invasive bladder cancer. In the double-blind...
PEACE-1 Trial: Addition of Abiraterone Plus Prednisone to ADT and Docetaxel in De Novo Metastatic Castration-Sensitive Prostate Cancer
As reported in The Lancet by Fizazi et al, the phase III PEACE-1 trial has shown that the addition of abiraterone and prednisone to androgen-deprivation therapy (ADT) and docetaxel improved radiographic progression-free survival and overall survival in patients with de novo metastatic...
Cheryl L. Willman, MD, on Cancer Genomic Sequencing in Tribal Nations of the American Southwest
Cheryl L. Willman, MD, of the Mayo Clinic Comprehensive Cancer Center, discusses the profound cancer health disparities among Native Americans, exacerbated by low rates of screening and limited access to care. Dr. Willman is heading an effort to promote community engagement in comprehensive genomic ...
Zev Wainberg, MD, on Gastroesophageal Junction Adenocarcinoma: Early Results With Anti-CD39 Antibody Plus Chemoimmunotherapy
Zev Wainberg, MD, of the University of California, Los Angeles Medical Center, discusses preliminary data on the safety and efficacy of TTX-030, an anti-CD39 antibody, in combination with budigalimab and FOLFOX for the first-line treatment of locally advanced or metastatic gastric or...
David A. Barbie, MD, on Mesothelioma: Activating the STING Pathway May Promote Antitumor Immunity
David A. Barbie, MD, of Dana-Farber Cancer Institute, discusses his laboratory’s studies, showing that malignant pleural mesothelioma, an inflamed cancer type with marginal response to immune checkpoint blockade, demonstrated high tumor cell STING expression and response to STING agonists in...
Jia Luo, MD, on NSCLC: Clinicopathologic and Molecular Characterization of KRAS G12D–Mutated Disease
Jia Luo, MD, of Dana-Farber Cancer Institute, discusses the emerging class of cancer therapies for allele-specific KRAS inhibitors and the importance of their distinct clinical, genomic, and immunologic features. Because KRAS G12D–mutated non–small cell lung cancer is associated with worse...
